Indivior Pharmaceuticals
INDV
198 hedge funds and large institutions have $2.68B invested in Indivior Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 93 funds opening new positions, 52 increasing their positions, 42 reducing their positions, and 14 closing their positions.
4,993% more call options, than puts
Call options by funds: $57M | Put options by funds: $1.12M
564% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 14
70% more capital invested
Capital invested by funds: $1.58B → $2.68B (+$1.1B)
65% more funds holding
Funds holding: 120 → 198 (+78)
24% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
85.73% less ownership
Funds ownership: 85.73% → 0% (-86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$5.16B |
| 2 |
Morgan Stanley
New York
|
+$106M |
| 3 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$67.5M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$66.3M |
| 5 |
BlackRock
New York
|
+$63.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$74.9M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$73.6M |
| 3 |
Goldman Sachs
New York
|
-$62.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$45.7M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$33.4M |
INDV Hedge Fund Activity: Q3 2025 in Review
198 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q3 2025, worth a combined $2.68B — up 70% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new INDV positions and 14 closed out — a net gain of 79 holders — while 52 added to existing stakes and 42 trimmed.
The largest buyer was Oaktree Capital Management, adding an estimated $5.16B. The largest seller was Deerfield Management, cutting an estimated $74.9M.
- 198 institutional investors held Indivior Pharmaceuticals (INDV) as of Q3 2025, up from 120 in Q2 2025.
- Funds reported $2.68B of Indivior Pharmaceuticals stock for Q3 2025, up 70% quarter-over-quarter.
- 93 funds opened new Indivior Pharmaceuticals positions in Q3 2025 and 14 closed out, a net change of +79 holders.
- The largest Indivior Pharmaceuticals buyer in Q3 2025 was Oaktree Capital Management, an estimated $5.16B added.
- The largest Indivior Pharmaceuticals seller in Q3 2025 was Deerfield Management, an estimated $74.9M sold.
Based on aggregated 13F filings for Q3 2025.